Mercure C, Thibault G, Lussier-Cacan S, Davignon J, Schiffrin E L, Reudelhuber T L
Medical Research Council Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Quebec, Canada.
J Biol Chem. 1995 Jul 7;270(27):16355-9. doi: 10.1074/jbc.270.27.16355.
The aspartyl protease renin, an important modulator of blood pressure in humans, is present in the circulation not only in its active form, but also as an inactive precursor, prorenin, in which a 43-amino acid prosegment blocks access of the substrate to the active site of the enzyme. Site-directed mutagenesis of the prosegment has led to the following conclusions. 1) Maintenance of the enzymatically inactive state of prorenin requires a short peptide sequence between positions 10P and 20P (where P denotes prosegment and numbering is relative to amino terminus) of the prosegment; and 2) there is an inverse relationship between the ability of prosegment mutations to activate and their effect on the secretion of the various prorenins, suggesting that this same region of the prosegment plays a critical role in the biosynthesis of human prorenin. Since these results demonstrated that single amino acid mutations could activate human prorenin to varying degrees, mutations in this region of the renin gene could be clinically important in humans. To test this hypothesis, genomic screening was carried out on the corresponding region of the human renin gene (exon 2) in a cohort of patients selected for a likely familial component to their hypertension. While this study identified a novel polymorphism in exon 2 of the human renin gene, evidence was not obtained for either the presence of prosegment mutations or the association of the novel polymorphism with hypertension in the patient population studied. In conclusion, both structure-function studies and genetic screening suggest that mutation of the prorenin prosegment is an unlikely factor in activation of the renin-angiotensin system in humans.
天冬氨酰蛋白酶肾素是人体血压的重要调节因子,它不仅以活性形式存在于血液循环中,还以无活性前体——肾素原的形式存在,其中一个43个氨基酸的前肽段会阻碍底物与酶活性位点的结合。对前肽段进行定点诱变得出了以下结论。1)肾素原的酶无活性状态的维持需要前肽段10P和20P位置之间(其中P表示前肽段,编号相对于氨基末端)的一个短肽序列;2)前肽段突变激活的能力与其对各种肾素原分泌的影响呈负相关,这表明前肽段的同一区域在人肾素原的生物合成中起关键作用。由于这些结果表明单个氨基酸突变可在不同程度上激活人肾素原,肾素基因该区域的突变在人类临床中可能具有重要意义。为验证这一假设,对一组因高血压可能存在家族因素而入选的患者的人肾素基因相应区域(外显子2)进行了基因组筛查。虽然这项研究在人肾素基因外显子2中发现了一种新的多态性,但在所研究的患者群体中未获得前肽段突变存在的证据,也未获得该新多态性与高血压关联的证据。总之,结构功能研究和基因筛查均表明,肾素原前肽段突变不太可能是人类肾素 - 血管紧张素系统激活的一个因素。